Efebera Discusses Different Regimens for Transplant-Eligible NDMM
November 23rd 2022During a Targeted Oncology case-based roundtable event, Yvonne A. Efebara, MD, MPH, discussed the role of triplet and quadruplet systemic therapies for newly diagnosed multiple myeloma and the use of autologous stem cell transplant.
Roundtable Discussion: Barata and Participants Explore Later-Line Options in Bladder Cancer
November 22nd 2022During a Targeted Oncology case-based roundtable event, Pedro Barata, MD, MSc, discussed with participants their approaches to therapy for a patient whose bladder cancer progresses after receiving chemotherapy and immunotherapy.
Managing Adverse Events of Nivolumab/Chemotherapy for Gastric/GEJ Cancers
November 18th 2022During a Targeted Oncology case-based roundtable event, Syma Iqbal, MD, discussed with participants their impressions of the CheckMate 649 chemoimmunotherapy regimen for patients with gastric/gastroesophageal junction cancers. This is the first of 2 articles based on this event.
Choosing Early-Line Therapy for NSCLC With an EGFR Exon 20 Insertion
November 16th 2022During a Targeted Oncology case-based roundtable event, Gregory Riely, MD, discussed the case of a patient with advanced non–small cell lung cancer who had an EGFR exon 20 insertion. This is the first of 2 articles based on this event.
Exploring the Background and Clinical Presentation of BPDCN
November 14th 2022During a Targeted Oncology case-based roundtable event, Jeffrey E. Lancet, MD, discussed the clinical presentation of blastic plasmacytoid dendritic cell neoplasm and how it came to be recognized as a distinct rare hematologic malignancy. This is the first of 2 articles based on this event.
Roundtable Discussion: The Role of Adjuvant Therapies for NSCLC Based on Disease Stage
November 14th 2022During a Targeted Oncology case-based roundtable event, Joel Neal, MD, PhD, and Leah Backhus, MD, MPH, discussed adjuvant therapies including chemotherapy, immunotherapy, and targeted therapy for patients with non–small cell lung cancer.
Roundtable Discussion: Ayyappan Breaks Down New and Emerging Approaches in DLBCL
November 13th 2022During a Targeted Oncology case-based roundtable event, Sabarish Ayyappan, MD, discussed with participants which therapy would be appropriate for an older patient with relapsed/refractory diffuse large B-cell lymphoma.
Discussing the LEAP-002 Trial of Lenvatinib Plus Pembrolizumab in HCC
November 9th 2022During a Targeted Oncology case-based roundtable event, Ghassan K. Abou-Alfa, MD, MBA, discusses with participants the unexpected results of the LEAP-002 trial of lenvatinib plus pembrolizumab versus pembrolizumab alone for patients with hepatocellular carcinoma. This is the second of 2 articles based on this event.
Roundtable Discussion: Salgia Looks at Testing and Treatment for NSCLC With EGFR Exon 20 Insertions
November 8th 2022During a Targeted Oncology case-based roundtable event, Ravi Salgia, MD, PhD, discussed with participants their approach to molecular testing and treatment of a patient diagnosed with non–small cell lung cancer.
Interpreting Results From New and Previous Trials of Lenvatinib in HCC
October 26th 2022During a live virtual event, Ghassan K. Abou-Alfa, MD, discussed the results of the REFLECT trial of lenvatinib versus sorafenib and the LEAP-002 trial of lenvatinib/pembrolizumab versus lenvatinib in patients with hepatocellular carcinoma.
Discussing Tolerability of Tivozanib as Third-Line Therapy for mRCC
October 24th 2022During a Targeted Oncology case-based roundtable event, Randy F. Sweis, MD, discussed with participants their experience with the tolerability of tivozanib for recurrent advanced renal cell carcinoma. This is the first of 2 articles based on this event.
Roundtable Discussion: Zonder Reviews Choice of Therapy for R/R Multiple Myeloma
October 20th 2022During a Targeted Oncology case-based roundtable event, Jeffrey Zonder, MD, discussed with participants the later-line therapy options for patients who have relapsed following several lines of treatment for multiple myeloma.
Reviewing Evidence for Therapies in NSCLC With EGFR Exon 20 Insertion
October 19th 2022During a Targeted Oncology case-based roundtable discussion, Zofia Piotrowska, MD, MHS, discussed the data from clinical trials supporting mobocertinib and amivantamab for patients with non–small cell lung cancer and an EGFR exon 20 insertion mutation.